INDV

At a glance

Indivior Pharmaceuticals, Inc. (INDV) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in North Chesterfield, United States and has 827 employees. The company is worth $4.17B and trades at 12.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $1.24B in fiscal 2025, up 4.3% from the year before. Net income was $210M. The share price is 17.5% below its 52-week high of $42.81. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Howard Marks (Oaktree Capital Management), at $251.4M. In that quarter, 3 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$4.17B

P/E

12.7x

Forward P/E

7.2x

P/B

—

Dividend yield

0.00%

Payout

—

EPS

$2.79

ROE

—

Profit margin

26.75%

Revenue growth

+13.60%

Beta

1.18

52-week high

$42.81

52-week low

$24.28

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• 
  Howard Marks− Reduced

  Oaktree Capital Management · Q2 2026
  $251.4M

  6.13M shares · 6.7% of portfolio
• 
  Ken Griffin− Reduced

  Citadel Advisors · Q2 2026
  $109.46M

  2.67M shares · 0.1% of portfolio
• IE
  Israel Englander− Reduced

  Millennium Management · Q2 2026

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

Fair price, seven ways

Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company